Business Context and Reporting Period
This Form 8-K Current Report, dated February 9, 2023, and signed on February 13, 2023, details a material definitive agreement and a public equity offering by Revelation Biosciences, Inc. The filing addresses the company's efforts to regain compliance with Nasdaq listing requirements regarding stockholders' equity and bid price.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $15.6 million from the sale of 2,888,600 shares of common stock, 336,400 pre-funded warrants, and accompanying common warrants.
- Net Proceeds: Estimated at approximately $14.1 million after accounting for offering expenses.
- Offering Price: $4.83 per share of Common Stock and associated Common Warrant; $4.8299 per Pre-Funded Warrant and associated Common Warrant.
- Warrant Terms: Common Warrants have an exercise price of $5.36 per share and expire five years from issuance. Pre-Funded Warrants have an exercise price of $0.0001 per share and do not expire.
- Transaction Costs: The Placement Agent received a cash fee of 8% of aggregate gross proceeds plus reimbursement of expenses and legal fees.
- Liquidity Impact: The offering resulted in stockholders' equity exceeding $2.5 million, addressing a specific Nasdaq listing deficiency.
Material Changes and Compliance Status
The primary material change is the successful closing of the Public Offering on February 13, 2023. Prior to this transaction, the company faced delisting risks from The Nasdaq Stock Market LLC due to non-compliance with the $1.00 minimum bid price rule and the $2.5 million stockholders' equity requirement. As of the filing date, the company has evidenced compliance with the $1.00 bid price requirement for nine consecutive business days (requiring ten) and has achieved the required stockholders' equity threshold through the offering proceeds.
Outlook, Risks, and Management Commentary
- Lock-Up Provisions: Company executive officers and directors are restricted from selling securities for 90 days following the closing. Institutional investors are subject to a leak-out arrangement limiting sales to 25% of the composite trading volume until April 10, 2023.
- Regulatory Risk: The company intends to notify Nasdaq of its compliance status, but final determination of continued listing remains subject to Nasdaq's review.
- Dilution: The offering includes significant warrant coverage (6,450,000 shares via Common Warrants), which may result in future dilution if exercised.
- Financial Statements: This filing does not contain audited financial statements, revenue, profit, or cash flow data for a reporting period; it focuses solely on the capital raise transaction.
Investor Verification Checklist
- Verify the final determination by Nasdaq regarding the company's continued listing status.
- Confirm the exact number of shares issued and the final net cash proceeds after all closing expenses.
- Monitor the stock price to ensure the company maintains the $1.00 bid price for the required ten consecutive business days.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.2) for specific representations and covenants.
- Assess the potential dilution impact of the 6,450,000 Common Warrants and 336,400 Pre-Funded Warrants.